News & Views - Page 43 of 52 - Telix Pharmaceuticals Limited

Telix Receives Approval for First-In-Human Study of Next Generation Prostate Cancer Therapy Product

Telix has been granted HREC approval and received CTN clearance by the TGA to commence Phase I study of the Company’s next generation prostate cancer therapy product TLX592, in patients with advanced prostate cancer.

Investor Briefing – TheraPharm GmbH Acquisition

Telix Pharmaceuticals Provides Investor Briefing: TheraPharm GmbH Acquisition.

Investor Conference Call: Telix’s acquisition of TheraPharm GmbH

Telix advises it will hold an investor conference call to provide further detail in relation to Telix’s acquisition of TheraPharm GmbH.

Telix Pharmaceuticals Limited Acquires TheraPharm GmbH

Telix announces it has entered into an agreement with Scintec Diagnostics GmbH to acquire TheraPharm GmbH, a Swiss-German biotechnology company developing innovative diagnostic and therapeutic solutions in the field of hematology.

Telix New Drug Application for Prostate Cancer Imaging Product Accepted by US FDA

Telix Pharmaceuticals announces New Drug Application (NDA) for TLX591-CDx (Kit for the preparation of 68Ga-PSMA-11)

Telix Presentation at the European Multidisciplinary Congress on Urological Cancers

Telix recently presented at the 12th European Multidisciplinary Congress on Urological Cancers entitled: “New Perspectives in Prostate and Kidney Cancer”.

Telix Receives €545,000 Belgian Research Grant for Prostate Cancer Imaging Agent in Europe

Advanced Nuclear Medicine Ingredients S.A. (ANMI) announces a €545,000 payment from the Walloon regional government in Belgium.

Telix presentations at European Association of Nuclear Medicine 2020 Satellite Symposium

Telix sponsored a session at the recent EANM20 Satellite Symposium, entitled “Next Generation Imaging with PSMA-PET & More”. For those unable to attend, we are pleased to provide recordings of live presentations held on 29th October 2020.

Investor Briefing: Telix Pharmaceuticals Limited and China Grand Pharma Partnership

Telix Pharmaceuticals Provides Investor Briefing: Our Asian Future

Telix Pharmaceuticals Limited and China Grand Pharma Announce Strategic Licence and Commercial Partnership for Greater China Market

Telix Pharmaceuticals Limited and China Grand Pharma Announce Strategic Licence and Commercial Partnership for Greater China Market.